Net Profit up 35% to Rs 333 crores
Agency Report October 22nd, 2020
Alembic Pharmaceuticals Limited reported its consolidated financial results for the quarter ending 30th September 2020.
Net Sales for the quarter up 17% to Rs 1457 crores from Rs. 1241 crores.
Net Profit for the quarter up 35% to Rs 333 crores from Rs 246 crores.
Net sales for H-1 FY21 up 28% to Rs 2798 crores against Rs 2190 crores.
Net profit for H-1 FY21 up 72% to Rs 635 crores from Rs 370 crores.
Mr. Pranav Amin, Managing Director, Alembic Pharmaceuticals Limited said “It was a strong quarter for the company led by growth in the domestic business. The International as well as API Business also continued to perform well.”
International formulations grew 21% to Rs 779 crores in the quarter and 41% to Rs 1550 crores for H-1.
US Generics grew 8% to Rs 582 crores in the quarter and 33% to Rs 1177 Crores for H-1.
Ex-US International Formulations grew 84% to Rs 197 crores in the quarter and 73% to Rs 373 Crores for H-1.
6 ANDA approvals received during the quarter; 131 Cumulative ANDA approvals.
7 ANDA filings during the quarter; Cumulative ANDA filings at 198.
India Formulations Business
India formulations business grew 6% to Rs 415 crores in the quarter and was Rs 721 crores for H-1.
API business grew 29% to Rs 263 crores in the quarter and 40% to Rs 528 crores for H-1.
2 DMF were filed in the quarter.